Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 4
2001 9
2002 32
2003 50
2004 44
2005 37
2006 52
2007 54
2008 49
2009 54
2010 37
2011 39
2012 34
2013 28
2014 35
2015 21
2016 22
2017 17
2018 14
2019 10
2020 7
2021 13
2022 10
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Results by year

Filters applied: . Clear all
Page 1
Yttrium 90 Ibritumomab Tiuxetan.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999770 Free Books & Documents. Review.
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is available on the use of yttrium 90 ibritumomab tiuxetan during breastfeeding. ...
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is avai …
Indium 111 Ibritumomab Tiuxetan.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999760 Free Books & Documents. Review.
Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is available on the use of indium 111 ibritumomab tiuxetan during breastfeeding. ...
Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is avail …
Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA).
Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. Mukherjee S, et al. Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):187-188. doi: 10.1016/j.hemonc.2017.12.004. Epub 2018 Feb 1. Hematol Oncol Stem Cell Ther. 2018. PMID: 29406240 Free article. Review.
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. ...
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the …
Zevalin() (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
Rizzieri D. Rizzieri D. Crit Rev Oncol Hematol. 2016 Sep;105:5-17. doi: 10.1016/j.critrevonc.2016.07.008. Epub 2016 Jul 16. Crit Rev Oncol Hematol. 2016. PMID: 27497027 Review.
Despite the efficacy and acceptable safety profile of ibritumomab tiuxetan, utilization has not been broadly adopted in practice due to a number of factors. This manuscript will review the literature available for ibritumomab tiuxetan, including severa …
Despite the efficacy and acceptable safety profile of ibritumomab tiuxetan, utilization has not been broadly adopted in practi …
Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB, Bondly C, Micallef IN. Johnston PB, et al. Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9. doi: 10.1586/14737140.6.6.861. Expert Rev Anticancer Ther. 2006. PMID: 16761929 Review.
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiux …
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hod …
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE. Witzig TE. Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. Drugs Today (Barc). 2004. PMID: 15045033 Review.
Tiuxetan is an MX-DTPA chelator that is linked to ibritumomab to form ibritumomab tiuxetan. Since yttrium-90 ((90)Y) is a pure beta emitter and cannot be used for patient imaging, indium-111 ((111)In) is chelated to ibritumomab tiuxetan for tumor and n …
Tiuxetan is an MX-DTPA chelator that is linked to ibritumomab to form ibritumomab tiuxetan. Since yttrium-90 ((90)Y) is a pure …
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr.
Mondello P, Cuzzocrea S, Navarra M, Mian M. Mondello P, et al. Oncotarget. 2016 Feb 16;7(7):7597-609. doi: 10.18632/oncotarget.6531. Oncotarget. 2016. PMID: 26657116 Free PMC article. Review.
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment of B-cell non-Hodgkin lymphoma (NHL), a remarkably radiosensitive hematologic malignancy. 90Y-IT activity has been well established in the …
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment …
Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma.
Desai S, Moustafa MA, Wiseman G, Witzig T. Desai S, et al. Oncologist. 2021 Nov;26(11):e2079-e2081. doi: 10.1002/onco.13895. Epub 2021 Jul 21. Oncologist. 2021. PMID: 34227176 Free PMC article.
External beam radiation therapy is curative in a substantial proportion of localized follicular lymphomas, but GI toxicities may discourage its use in PGIFL. Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody lin …
External beam radiation therapy is curative in a substantial proportion of localized follicular lymphomas, but GI toxicities may discourage …
Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN. Micallef IN. Clin Lymphoma. 2004 Oct;5 Suppl 1:S27-32. doi: 10.3816/clm.2004.s.006. Clin Lymphoma. 2004. PMID: 15498147 Review.
Yttrium 90 ibritumomab tiuxetan has been shown to be efficacious in the treatment of B-cell NHL. ...This article reviews the ongoing trials with 90Y ibritumomab tiuxetan. Radioimmunotherapy has great promise, and the safe incorporation of 90Y ibritu …
Yttrium 90 ibritumomab tiuxetan has been shown to be efficacious in the treatment of B-cell NHL. ...This article reviews the o …
Yttrium 90 ibritumomab tiuxetan in lymphoma.
Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Cheung MC, et al. Leuk Lymphoma. 2006 Jun;47(6):967-77. doi: 10.1080/10428190600572582. Leuk Lymphoma. 2006. PMID: 16840185 Review.
A total of twenty trials investigating the use of 90Y-ibritumomab tiuxetan for the treatment of adult patients with NHL were identified. ...However, in rituximab-naive patients with relapsed or refractory indolent or transformed NHL, the higher response rate seen wi …
A total of twenty trials investigating the use of 90Y-ibritumomab tiuxetan for the treatment of adult patients with NHL were i …
619 results